By mid-2026, the industry has officially entered the era of "Cross-System Analysis." This year, the focus is on the "Heart-Kidney Axis," where clinicians use serial BNP measurements to predict the onset of chronic kidney disease (CKD) before traditional creatinine levels even begin to rise. This innovation is a primary driver for the market, as recent clinical trials in late 2025 demonstrated...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek